Compile Data Set for Download or QSAR
Report error Found 28 Enz. Inhib. hit(s) with all data for entry = 3435
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33999(arylalkyne pyrazole-based compound, 33)
Affinity DataIC50: 40nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM34000(tetrahydropyrido-pyrazole, 1)
Affinity DataIC50: 120nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33994(arylalkyne pyrazole-based compound, 28)
Affinity DataIC50: 140nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33987(arylalkyne pyrazole-based compound, 18)
Affinity DataIC50: 200nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33998(arylalkyne pyrazole-based compound, 32)
Affinity DataIC50: 220nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33997(arylalkyne pyrazole-based compound, 31)
Affinity DataIC50: 280nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33988(arylalkyne pyrazole-based compound, 19)
Affinity DataIC50: 280nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33989(arylalkyne pyrazole-based compound, 20)
Affinity DataIC50: 280nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33996(arylalkyne pyrazole-based compound, 30)
Affinity DataIC50: 310nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33993(arylalkyne pyrazole-based compound, 24)
Affinity DataIC50: 320nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33995(arylalkyne pyrazole-based compound, 29)
Affinity DataIC50: 330nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33991(arylalkyne pyrazole-based compound, 22)
Affinity DataIC50: 430nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33990(arylalkyne pyrazole-based compound, 21)
Affinity DataIC50: 480nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33992(arylalkyne pyrazole-based compound, 23)
Affinity DataIC50: 510nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33984(arylalkyne pyrazole-based compound, 15)
Affinity DataIC50: 550nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33977(arylalkyne pyrazole-based compound, 8)
Affinity DataIC50: 610nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33985(arylalkyne pyrazole-based compound, 16)
Affinity DataIC50: 700nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33981(arylalkyne pyrazole-based compound, 12)
Affinity DataIC50: 720nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33978(arylalkyne pyrazole-based compound, 9)
Affinity DataIC50: 790nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33983(arylalkyne pyrazole-based compound, 14)
Affinity DataIC50: 870nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33982(arylalkyne pyrazole-based compound, 13)
Affinity DataIC50: 1.10E+3nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33986(arylalkyne pyrazole-based compound, 17)
Affinity DataIC50: 1.50E+3nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33979(arylalkyne pyrazole-based compound, 10)
Affinity DataIC50: 1.50E+3nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33976(arylalkyne pyrazole-based compound, 7)
Affinity DataIC50: 6.70E+3nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33980(arylalkyne pyrazole-based compound, 11)
Affinity DataIC50: 7.40E+3nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33973(arylalkyne pyrazole-based compound, 4)
Affinity DataIC50: 7.90E+3nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33975(arylalkyne pyrazole-based compound, 6)
Affinity DataIC50: 8.30E+3nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed
TargetCathepsin S(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM33974(arylalkyne pyrazole-based compound, 5)
Affinity DataIC50: 1.10E+4nMpH: 5.0 T: 2°CAssay Description:Enzyme assays were run using fluorescence resonance energy transfer-based substrates, (Aedens)EKARVLAEAA(Dabcyl)K-amide and cathepsin S cleaves betwe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2009
Entry Details Article
PubMed